• 241 Accesses

Abstract

Drug-induced lung disease, also known as drug-induced lung damage, is the lung damage caused by drugs and their metabolites through direct cytotoxicity or allergic immune reactions, as a part of systemic adverse reactions caused by drugs. Previous studies have reported that lung damage accounts for 6–7% of adverse drug reactions [1]. More than 350 kinds of drugs can cause lung damage. Drugs with lung toxicity include chemotherapy drugs, antibiotics, cardiovascular drugs, nonsteroidal anti-inflammatory drugs, etc. Drug-induced lung damage caused by cytotoxic chemotherapy drugs is the most common. In recent years, drug-induced lung damage has been increasing year by year with the emergence of biological agents, new anti-tumor targeted drugs, and programmed death protein 1 (PD-1) immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Kubo K, Wan X. On drug-induced lung damage. Prog Jap Med. 2007;28(3):98–9.

    Google Scholar 

  2. Sun X, Zhu Y, Feng Y, et al. Analysis of anti-tumor targeted drugs induced lung disease. Chin Pharm J. 2018;53(16):1425–30.

    Google Scholar 

  3. Wang Q, Wu X. Clinical manifestations and treatment of immune-related adverse reactions in the therapy by immune checkpoint inhibitors. Chin J Immunol. 2017;33(4):615–20.

    Google Scholar 

  4. Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3(10):1185–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, et al. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med. 2011;124(5):386–94.

    Article  CAS  PubMed  Google Scholar 

  6. Xu Z. Attention to and understanding of drug-induced lung injury should be strengthened. Chin J Tubercul Resp Dis. 2017;40(10):721–3.

    CAS  Google Scholar 

  7. Zhao MX, Zhang WF. Early detection value of 18F-FDG-PET/CT for drug-induced lung injury in lymphoma. Ann Hematol. 2019;98(4):909–14.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Science Press

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Xu, Y. (2023). Drug-Induced Lung Disease. In: Li, H., Liu, J., Li, L. (eds) Radiology of Infectious and Inflammatory Diseases - Volume 3. Springer, Singapore. https://doi.org/10.1007/978-981-99-4614-3_24

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-4614-3_24

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-4613-6

  • Online ISBN: 978-981-99-4614-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Navigation